Stock listing

Dusseldorf:KH6 NewAmsterdam Pharma Company N.V. Aktie

German listing (Dusseldorf) of NewAmsterdam Pharma Company N.V. · home listing NASDAQ:NAMS

Follow NewAmsterdam Pharma Company N.V. into a list and get an email when it puts out news.

Share price · DUS:KH6

€17.86 EUR -0.21 (-1.2%)

Close on Nov 5, 2026

Day range
€17.86 – €18.39 EURNov 5, 2026
NewAmsterdam Pharma Company N.V. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NAMS · Home$20.93 USD+1.03 (+5.2%)1,889,340$22.26$22.26$19.81$19.90Close on Nov 4, 2026
Dusseldorf:KH6€17.86 EUR-0.215 (-1.2%)—€18.36€18.39€17.86€18.07Close on Nov 5, 2026
Frankfurt:KH6€18.02 EUR-0.11 (-0.6%)—€17.69€18.02€17.69€18.13Close on Nov 5, 2026
Ticker
Dusseldorf:KH6
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Calls

Replays

  • NewAmsterdam Pharma (NASDAQ:NAMS) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 9:00 AM ET

    Watch Transcript

  • NewAmsterdam Pharma (NASDAQ:NAMS) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2026

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Nov 4, 2026

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November

Nov 3, 2026

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

Sep 29, 2026

Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

Sep 21, 2026

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

Sep 2, 2026

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Aug 26, 2026

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

Jul 29, 2026

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

Jun 3, 2026

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

May 11, 2026

All NewAmsterdam Pharma Company N.V. news

Financings

  • Public offering of ordinary shares and pre-funded warrants

    Dec 11, 2024

    Made bigger: about US$416.5M · US$24.5 a share · Jefferies +5

    Dealers: Jefferies (co-lead), Goldman Sachs & Co. (co-lead), Leerink Partners (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), William Blair (co-lead)

    Announced Dec 10, 2024 · Made bigger Dec 11, 2024

Read by 6ix AI from the company's releases

Decks

NewAmsterdam Pharma Company N.V. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 93 in all · newest Nov 6, 2026 · oldest 2022
Calls
2 calls with a replay · 2 with a transcript · latest Aug 5, 2026
Decks
33 decks · latest Nov 4, 2026

Where NewAmsterdam Pharma Company N.V. is listed

ListingExchangeCountryCurrency
NASDAQ:NAMS · Home listingNASDAQUnited StatesUSD
gettex:KH6gettexGermanyEUR
LS Exchange:A3DUACLS ExchangeGermanyEUR
Tradegate:KH6TradegateGermanyEUR
BOATS:NAMSBOATSUnited StatesUSD
Lang & Schwarz:A3DUACLang & SchwarzGermanyEUR
Dusseldorf:KH6 · This pageDusseldorfGermanyEUR
Frankfurt:KH6FrankfurtGermanyEUR
Hamburg:KH6HamburgGermanyEUR
Munich:KH6MunichGermanyEUR
Stuttgart:KH6StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about NewAmsterdam Pharma Company N.V.